AKTX: Akari Therapeutics PLC Company Value to Net Income

Akari Therapeutics, Plc - graphic logo of issuer AKTX

Akari Therapeutics (AKTX) is implementing ESG principles by reducing laboratory emissions and transitioning to eco-friendly packaging. The company's viability relies on the success of nomacopan in treating rare pathologies and the pursuit of new investments. This daily price chart featuring the -0.50 indicator demonstrates the current share price, which already prices in asset merger costs and the anticipation of fresh clinical reports.

Akari Therapeutics Plc (AKTX) Price to Earnings Ratio: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Akari Therapeutics, Plc (AKTX)

- price and consensus price forecast:
Comprehensive company analysis:Akari Therapeutics Plc AKTX
Signature product of Akari Therapeutics plc

The specifics of Akari Therapeutics (AKTX) biopharmaceutical development exclude the influence of economic cycles, shifting primary risks into the realm of clinical trials. Daily comparison of the business's market value against net income via the company's fundamental P/E allows for an assessment of the cost of each unit of income, helping investors determine the degree of asset overvaluation and the risk of multiple compression during periods of tight monetary policy.

Key competitors

P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Business Payback Period KalVista Pharma (KALV)|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Price to Earnings Ratio|Market Cap to Net Income RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Company Value to Net Income|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics, Inc - P/E Multiple|Market Cap to Net Income TLSA|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Bio|Price to Earnings Ratio Theratechnologies, Inc.|Market Cap to Earnings Avalo Therapeutics AVTX|P/E Multiple ELDN|AGEN (Agenus, Inc.) - Company Value to Net Income|Price to Earnings Ratio Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Market Cap to Earnings|ATYR: Price to Earnings Ratio|adagene.com (ADAG) - Price to Earnings Ratio|Ikena Oncology (IMA) - Price to Earnings Ratio|Price to Earnings Ratio Shattuck Labs, Inc.|Price to Earnings Ratio equilliumbio.com|Price to Earnings Ratio connectbiopharm.com (CNTB)|P/E Multiple IMUX|Business Payback Period Atara Bio|Price to Earnings Ratio InflaRx N.V. IFRX|X4 Pharmaceuticals - Price to Earnings Ratio|ACET: Price to Earnings Ratio|Company Value to Net Income CELU (celularity.com)|INMB: P/E Multiple|BRNS: Market Price to Net Income Ratio|KZR (Kezar Life Sciences, Inc.) - P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Business Payback Period|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd.)|Price to Earnings Ratio Q32 Bio Inc QTTB|Price to Earnings Ratio geovax.com GOVX|P/E Multiple edesabiotech.com EDSA|iBio Corporation - P/E Multiple|Company Value to Net Income CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Bio (BOLT) - P/E Multiple|HCWB (HCW Biologics Inc) - P/E Multiple|Price to Earnings Ratio Aptevo Therapeutics (APVO)|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple